NOT-DA-22-015: Notice of NIDA's Participation in NOT- MD-21-008 "Notice of Special Interest (NOSI): Research to Address Vaccine Hesitancy, Uptake, and Implementation among Populations that Experience Health Disparities"

Notice of NIDA's Participation in NOT- MD-21-008 "Notice of Special Interest (NOSI): Research to Address Vaccine Hesitancy, Uptake, and Implementation among Populations that Experience Health Disparities"

Notice Number:

NOT-DA-22-015

Key Dates

Release Date:

January 26, 2021

Related Announcements

PA-20-183 - Research Project Grant (Parent R01 Clinical Trial Required)

PA-20-185 - NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)

PA-20-194 - NIH Exploratory/Developmental Research Grant Program (ParentR21Clinical Trial Required)

PA-20-195 - NIH Exploratory/Developmental Research Grant Program (ParentR21Clinical Trial Not Allowed)

PA-20-196 - NIH Exploratory/Developmental Research Grant Program (Parent R21 Basic Experimental Studies with Humans Required)

PA-20-135 - Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement - Clinical Trial Optional)

PA-20-272 - Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)

NOT-MD-21-008 - Notice of Special Interest (NOSI): Research to Address Vaccine Hesitancy, Uptake, and Implementation among Populations that Experience Health Disparities

Issued by

National Institute on Drug Abuse (NIDA)

Purpose

The purpose of this Notice is to inform potential applicants that the National Institute on Drug Abuse (NIDA) will participate, effective immediately in NOT-MD-21-008, Notice of Special Interest (NOSI): Research to Address Vaccine Hesitancy, Uptake, and Implementation among Populations that Experience Health Disparities”.

The following sections of NOT-MD-21-008 have been modified (shown in italics):

Part 1. Overview Information

Components of Participating Organizations

National Institute on Drug Abuse (NIDA)

Institute Interests

NIDA seeks to support research in addressing SARS-CoV-2 vaccine implementation among populations with current substance use and substance use disorders, particularly those from NIH-designated U.S. health disparity populations (see a full description at https://www.nimhd.nih.gov/about/overview/ ). Additionally, NIDA is interested in research on understanding and increasing engagement in SUD vaccine clinical trials among health disparity populations.

Areas of special interest include but are not limited to the following:

Effective ways to vaccinate substance using populations who are not currently engaged in treatment
Effective ways to mobilize community resources (e.g., community organizations, social networks) to increase vaccine delivery to individuals with substance use disorder who are experiencing homelessness or who are marginally housed
Increased understanding of how models for outreach to and engagement of individuals with substance use disorder (e.g., peer navigators, peer educators, peer recovery coaches, mobile outreach services) can be adapted for implementing SARS-CoV-2 vaccination in similar populations
Increased understanding of how stigma and misinformation serve as barriers to receipt of SARS-CoV-2 and SUD vaccinations
Approaches for encouraging widespread vaccination among persons who are in treatment for substance use disorders
Increased understanding of the representation of health disparity populations in SUD vaccine trials,
Increased understanding of health disparity populations’ attitudes about and interest in participating in SUD vaccine clinical trials
Increased understanding of barriers that health disparity populations face when accessing SUD vaccines
Strategies and interventions to increase access to SUD vaccines for health disparity populations